Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03120624 · ClinicalTrials.gov registry record · Phase 1

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

A Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Endometrial Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.

Active
Registry status
Phase 1
Development phase
34
Enrollment target
1
Study location

NCT03120624 is a Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Endometrial Endometrioid Adenocarcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 34 participants, below the 251-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03120624, a Phase 1 study of Recurrent Endometrial Carcinoma and Recurrent Endometrial Endometrioid Adenocarcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.

Conditions Studied

Recurrent Endometrial Carcinoma Recurrent Endometrial Endometrioid Adenocarcinoma Metastatic Endometrial Carcinoma Recurrent Endometrial Serous Adenocarcinoma Recurrent Endometrial Clear Cell Adenocarcinoma Recurrent Endometrial Adenocarcinoma Stage IV Uterine Corpus Cancer AJCC v7 Recurrent Endometrial Mixed Cell Adenocarcinoma Recurrent Endometrial Undifferentiated Carcinoma Recurrent Uterine Corpus Carcinosarcoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • PROCEDURE Positron Emission Tomography
  • OTHER Pharmacological Study
  • OTHER Fluorine F 18 Tetrafluoroborate

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2017-09-15
Est. Completion 2028-01-01
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03120624

The ClinicalTrials.gov registry entry for NCT03120624 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 251-participant average among 19 other Recurrent Endometrial Carcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Endometrial Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT03120624 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03120624 about?

NCT03120624 is a clinical study titled "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer". This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study vir...

What is the current status of trial NCT03120624?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-09-15. Estimated completion is 2028-01-01.

What conditions does trial NCT03120624 study?

This clinical trial studies the following conditions: Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma.

What interventions are being tested in trial NCT03120624?

The interventions under investigation include: Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Pharmacological Study (OTHER), Fluorine F 18 Tetrafluoroborate (OTHER).

Who is sponsoring clinical trial NCT03120624?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03120624 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Endometrial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Endometrial Carcinoma

All registered trials for this condition

Recurrent Endometrial Endometrioid Adenocarcinoma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.